Pfizer to acquire cancer drug company Medivation

Pfizer is to acquire cancer drug company Medivation in a deal valued at about US$14bn.

Pfizer to acquire cancer drug company Medivation

Pfizer is to acquire cancer drug company Medivation in a deal valued at about US$14bn.

Medivation is best known for cancer treatment Xtandi, which it jointly markets with Japanese drug maker Astellas Pharma.

Already a subscriber? Sign in

You have reached your article limit.

Subscribe to access all of the Irish Examiner.

Annual €130 €80

Best value

Monthly €12€6 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited